Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 7/20 | 0.33 |
| ▸ | CNR1 | P21554 | 6/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796610 | 0.96 | CNR2 (0.34) | CYP3A4CYP2C9CNR2CNR1FFAR4 | |
| SCHEMBL19796996 | 0.95 | CYP2C9 (0.35) | CYP3A4CYP2C9CNR2CNR1FFAR4 | |
| SCHEMBL19796526 | 0.95 | CYP3A4 (0.35) | CYP3A4CYP2C9CNR2CNR1FFAR4 | |
| SCHEMBL19797004 | 0.94 | CNR2 (0.33) | CYP3A4CYP2C9CNR2CNR1FFAR4 | |
| SCHEMBL19796647 | 0.92 | CYP3A4 (0.35) | CYP3A4CYP2C9FFAR4PPARDFASN | |
| SCHEMBL19796562 | 0.92 | CNR2 (0.34) | CYP2C9CNR2CNR1FFAR4TSHR | |
| SCHEMBL19797002 | 0.92 | CYP3A4 (0.35) | CYP3A4CYP2C9CNR2CNR1FFAR4 | |
| SCHEMBL19797020 | 0.91 | CNR2 (0.35) | CYP3A4CYP2C9CNR2CNR1FFAR4 | |
| SCHEMBL19797015 | 0.90 | CYP3A4 (0.34) | CYP3A4CYP2C9FFAR4PPARDFASN | |
| SCHEMBL19796552 | 0.90 | TSHR (0.33) | CYP3A4CYP2C9CNR2CNR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CYP3A4 2192/4885CYP2C9 4202/4885CNR2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.